menu search

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Continues to advance development of AQST-109 (epinephrine sublingual film); received FDA conditional approval of brand name Anaphylm™ Raises full year 2023 revenue and non-GAAP adjusted EBITDA guidance Reaffirms commitment to pursue early market access for Libervant™ (diazepam) Buccal Film Obtains dismissal of outstanding shareholder lawsuits Generated $47 million non-dilutive cash in the last 12 months […] The post Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides... Read More
Posted: May 2 2023, 20:31
Author Name: forextv
Views: 092158

Search within

Pages Search Results: